About the Program
McMaster University offers a two-year sub-specialty residency training program in gynecologic oncology with the option of a one-year clinical research position. This program is accredited by the Royal College of Physicians and Surgeons of Canada. The residency position is funded by the Ministry of Health and Long Term Care. One resident is awarded a residency position every year.
The program provides educational exposure to an extensive variety of clinical and surgical cases in the field of gynecologic oncology, including advanced laparoscopic surgery, multi-visceral cytoreductive surgery, sentinel lymph node mapping and systemic therapy.
According to the requirements of the Royal College of Physicians and Surgeons of Canada, core rotations include:
- Radiation oncology (2 blocks)
- Medical oncology (2 blocks)
- Intensive care unit (1 block)
- Elective (1 block)
- Gynecologic oncology (18 blocks)
Surgical training is enriched with a longitudinal six-month rotation in vascular surgery and surgical selective opportunities including colorectal surgery, robotic surgery and colposcopy. Protected research and academic time is also ensured to optimize medical knowledge in the management of gynecologic malignancies and to contribute to advancement in the field. Funding for attendance and presentation at the national and international meetings is available. Mentorship from distinguished academic faculty, including five gynecologic oncologists, three radiation oncologists, and two medical oncologists, combined with an abundant volume of complex cases, provides for an exceptional training experience.
The primary training site is the Juravinski Hospital and Cancer Centre. Patients are referred from within the Hamilton Niagara Haldimand Brant (HNHB) Local Health Integration Network (LHIN), which also includes Burlington and most of Norfolk, an area that includes a diverse population of over 1.4 million people.
In conjunction with the vast range of clinical and surgical cases, research support and mentorship and the innovative and patient-centered approach of Hamilton Health Sciences, the residency training program in gynecologic oncology at McMaster University is positioned to provide residents with an outstanding training opportunity.
Electives
For information on electives in gynecologic oncology, please visit our electives page prior to the contacting the electives coordinator.
Application Process
Starting January 1, 2024, we will accept applications for the 2025/2026 academic year. The deadline date for 2025/2026 applications is May 31, 2024.
For further information on how to apply, required documentation and to submit your application, please visit the visit the Fellowship Application Portal. Reference letters are to be addressed to the program director and emailed directly to the fellowship program coordinator. Under the reference section of the application, please upload a document listing your referees and their contact information. Inquiries regarding the program should be emailed to the fellowship program coordinator.
Incomplete applications with missing documents will not be considered.
Program Directors and Committee Members
Information Box Group
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
Waldo Jimenez
MD
Associate Professor, Division Lead Gynaecologic Oncology
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Waldo Jimenez
MD
Associate Professor, Division Lead Gynaecologic Oncology
Gynecologic Oncology
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
Julie Nguyen
MD
Assistant Professor
Gynecologic Oncology
Julie Nguyen is an Assistant Professor in the Department of Obstetrics and Gynecology at McMaster University. She is an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre (JHCC). She completed her residency and fellowship training at the University of Toronto. Upon completing a Masters of Science in Healthcare Improvement and Patient Safety, she has developed and published on several multidisciplinary perioperative improvement projects, including initiatives to decrease surgical site infections and thromboembolic events after Gynecologic Oncology surgery as well as an opioid stewardship strategy.
The main focus of her clinical research is to define the impact of frailty and aging on perioperative outcomes and tolerance to chemotherapy in Gynecologic Oncology to in turn develop strategies to optimize modifiable risk factors. She is the co-PI of the FARGO study, a multicenter prospective study which investigates the impact of frailty and its biomarkers on surgical and oncologic outcomes in patients over the age of 55. In parallel, she conducts population-level cohort studies utilizing databases such as CLSA, IC/ES, and NSQIP to further investigate frailty and aging. Her second focus of research is on equity, diversity and inclusion in the medical learning and working environments. She mentors numerous undergraduate and postgraduate students in research. She has been awarded greater than $800,000 in grant funding since 2020, from Hamilton Health Sciences (HHS), the Juravinski Hospital and Cancer Centre Foundation, the McMaster Institute for Research on Aging, HAHSO, the Population Health Research Institute and the Department of Obstetrics and Gynecology. She has received multiple awards including the Early Career Research Award from HHS, and the Most Promising Research award from the Department of Obstetrics and Gynecology.
Dr. Nguyen holds several leadership roles at both local and national levels. She serves as co-chair of the Gynecologic Oncology Disease Site Team at JHCC, as chair of the Business Unit, and co-chair of the Quality Improvement and Patient Safety Community of Practice, at the Society of Gynecologic Oncology of Canada. Additionally, she oversees the academic half-day curriculum for the Gynecologic Oncology Fellowship program at McMaster University.
For a comprehensive list of her publications, please visit her Google Scholar Profile: https://scholar.google.com/citations?user=W0CJcx8AAAAJ&hl=en&oi=sra
Julie Nguyen
MD
Assistant Professor
Gynecologic Oncology
Nidhi Kumar Tyagi
MBChB, MSc, FRCPC
Medical Oncology
Nidhi Kumar Tyagi
MBChB, MSc, FRCPC
Medical Oncology
Elysia Donovan
MD, MSc, FRCPC, DABR
Radiation Oncology
Elysia Donovan
MD, MSc, FRCPC, DABR
Radiation Oncology
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Lua Eiriksson
MD, MPH, FRCSC, FACS
Associate Professor
Gynecologic Oncology
BIO
Lua R. Eiriksson completed her medical degree at Dalhousie University and residency in obstetrics and gynecology at the University of Alberta. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret Cancer Centre and Odette/Sunnybrook Cancer Centre), and obtained a masters in public health in epidemiology from the University of Toronto’s Dalla Lana School of Public Health. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster University since 2013.
RESEARCH INTERESTS
Current research interests include cervical cancer prevention and health advocacy, universal screening for Lynch Syndrome in patients with endometrial and epithelial ovarian cancer, the use of risk of malignancy scoring in patients with suspected ovarian cancer, occupational exposures and ovarian cancer risk, quality indicators in clinical practice and centre-specific patient outcomes by disease site and treatment received. She is involved with the MD program as a student advisor, tutor, lecturer, mentor for simulation training and clinical mentor. She is also involved with the obstetrics and gynecology program as an ombudsmen, a member of the Obstetrics & Gynecology Surgical Curriculum Committee, Objective Structured Clinical Examination (OSCE) supervisor, lecturer, clinical mentor and research project supervisor. She is also a member of the New Patient Referral Project Quality Improvement Working Group at the Juravinski Cancer Centre.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Eiriksson, L., Aronson, M., Clarke, B., Mojtahedi, G., Massey, C., Oza, A.M., Gallinger, S., Pollett, A., Mackay, H., Bernardini, M.Q. and Ferguson, S.E., 2015. Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic oncology, 136(2), pp.311-316.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS?0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Ferguson, S.E., Aronson, M., Pollett, A., Eiriksson, L.R., Oza, A.M., Gallinger, S., Lerner?Ellis, J., Alvandi, Z., Bernardini, M.Q., MacKay, H.J. and Mojtahedi, G., 2014. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 120(24), pp.3932-3939.
Eiriksson, L. and Covens, A., 2012. Advancing fertility-sparing treatments in cervical cancer: Where is the limit?. Gynecologic Oncology, 126, pp.317-8.
Eiriksson, L., Kaur, H., Ismiil, N., Barbera, L. and Covens, A., 2013. The significance of primary tumor factors and treatment received in risk of recurrence in clinical stage I high-grade endometrial adenocarcinoma. Gynecologic Oncology, 130(1), p.e72.
Ferguson, S.E., Aronson, M., Eiriksson, L.R., Mojtahedi, G., Pollett, A., Gallinger, S., Oza, A.M., Mackay, H., Bernardini, M., Lerner-Ellis, J. and Clarke, B., 2013. Screening for Lynch syndrome in unselected women with endometrial cancer. Journal of Clinical Oncology, 31(15 suppl), pp. 5508-5508.
Eiriksson, L., Harris, M., Hardt, J., Tjepkema, M., Peters, P. and Demers, P., 2013. Occupational exposures and ovarian cancer: A national population-based cohort study. Gynecologic Oncology, 130(1), pp.e142-e143.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L., Wells, T., Steed, H., Schepansky, A., Capstick, V., Hoskins, P., Pike, J. and Swenerton, K., 2012. Combined methotrexate–dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecologic oncology, 124(3), pp.553-557.
Kaur, H., Eiriksson, L., Saad, R., Khalifa, M., Dube, V., Ghorab, Z., Covens, A., Barbera, L. and Ismiil, N., 2012, February. Prognostic Significance of Primary Tumour Factors in Stage III High Grade Endometrial Cancer. Laboratory Investigation, 92, pp. 280A-280A).
Eiriksson, L.R. and Covens, A., 2012. Sentinel lymph node mapping in cervical cancer: the future?. BJOG: An International Journal of Obstetrics & Gynaecology, 119(2), pp.129-133.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Eiriksson LR, Covens A. Follow-up after chemoradiation for cervical cancer: Why? Cancer. 2011;117(17):3875-8.
Eiriksson L, Covens A. Fertility-Sparing Surgery in Cervical Cancer. European Obstetrics & Gynaecology. 2011;6(1):52-5.
Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, Faught W, Dundas G. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. International Journal of Gynecologic Cancer. 2010 Nov;20(8):1356-62.
Eiriksson L, Covens A. Conservative surgery for early stage cervical cancer: who should we offer it to? Gynecology Oncology. 2010;119(2)173-4.
Waldo Jimenez
MD
Associate Professor, Division Lead Gynaecologic Oncology
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Waldo Jimenez
MD
Associate Professor, Division Lead Gynaecologic Oncology
Gynecologic Oncology
BIO
Dr. Waldo Jimenez completed his degree in medicine at Universidad de Concepcion, Chile in 1997. He completed residency training in obstetrics and gynecology at Universidad Catolica, Chile in 2000. He then went on to complete a masters in clinical epidemiology at the University of Toronto in 2007, while also completing his fellowship in obstetrics and gynecology at the University of Toronto in 2008.
Dr. Jimenez was an assistant professor in the Department of Obstetrics & Gynecology, Universidad Catolica, Concpecion, Chile from 2000–05. He then became an assistant professor in the Department of Obstetrics & Gynecology at the University of Toronto, Credit Valley Hospital from 2008–10. Dr. Jimenez became an assistant professor in the Department of Obstetrics & Gynecology at McMaster University, Juravinski Cancer Centre in 2010, and since 2016 has held the rank of associate professor.
AWARDS
2012 – McMaster University, Council on Resident Education in Obstetrics and Gynecology (CREOG) National Faculty Award for Excellence in Resident Education
RESEARCH INTERESTS
Ongoing Research
Prospective cohort study evaluating identification rate of sentinel node in the management of endometrial cancer utilizing a combined method of cervical and myometrial injections.
Role: principal investigator
Grant: Juravinski Cancer Centre Foundation
PUBLICATIONS
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361
Rosen, B., Dodge, J., Giede, C., Jimenez, W., Cibulska, P., Sinesat, S., Bernardini, M., Mcalpine, J., Finlayson, S., Miller, D. and Elkanah, O., 2012. Implementation of oncology surgery in Western Kenya. Canadian Medical Association Journal, 55(4), p.284.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Prévention du cancer du col utérin au sein de milieux ne disposant que de faibles ressources. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.280-288.
Elit, L., LaRoche, A., Smith, L., Mazurka, J., Moens, F., Hauspy, J. and Jimenez, W., 2011. Management of women with surgically staged 1 uterine papillary serous cancer. ISRN obstetrics and gynecology, 2011.
Elit, L., Jimenez, W., McAlpine, J., Ghatage, P., Miller, D. and Plante, M., 2011. Cervical cancer prevention in low-resource settings. Journal of Obstetrics and Gynaecology Canada, 33(3), pp.272-279.
Hauspy, Jan, Waldo Jiménez, Barry Rosen, Walter H. Gotlieb, Michael Fung-Kee-Fung, and Marie Plante. “Laparoscopic surgery for endometrial cancer: a review.” Journal of Obstetrics and Gynaecology Canada 32, no. 6 (2010): 570-579.
Gortzak-Uzan, L., Jimenez, W., Nofech-Mozes, S., Ismiil, N., Khalifa, M.A., Dubé, V., Rosen, B., Murphy, J., Laframboise, S. and Covens, A., 2010. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?. Gynecologic oncology, 116(1), pp.28-32.
Elit, L.M., Rosen, B., Jimenez, W., Giede, C., Cybulska, P., Sinasac, S., Dodge, J., Ayush, E., Omenge, O., Bernardini, M. and Finlayson, S., 2010. Teaching cervical cancer surgery in low-or middle-resource countries. International Journal of Gynecological Cancer, 20(9), pp.1604-1608.
Jiménez, W., Paszat, L., Kupets, R., Wilton, A. and Tinmouth, J., 2009. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecologic oncology, 114(3), pp.395-398.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.
Clare Reade
MD, MSc, FRCSC
Assistant Professor
Gynecologic Oncology
BIO
Clare J. Reade completed her medical degree and residency in obstetrics and gynecology at McMaster University. She completed a three-year fellowship in gynecologic oncology at the University of Toronto (Princess Margaret and Odette/Sunnybrook Cancer Centres), and obtained her MSc from the health research methodology (HRM) program at McMaster University. Her master’s degree area of specialization is health technology assessment and health economics. She has been a gynecologic oncologist at the Juravinski Cancer Centre and an assistant professor in the Department of Obstetrics & Gynecology at McMaster since 2014.
AWARDS
2013: First Prize Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: People’s Choice Award: Best Oral Abstract – Gynecologic Oncology Canada Annual Meeting
2013: International Society for the Study of Trophoblastic Diseases (ISSTD) Scholarship for the World Congress XVII
2013: Dr. J.W. Knox Ritchie Research Award – University of Toronto Department of Obstetrics & Gynecology Research Day Award
2012: Justice Emmett Hall Foundation Health Services/Health Policy Research Masters level award for best policy paper
2012: Health Research Methodology program MSc student publication award
2010: GOC-Ovarian Cancer Canada Bruce Galloway Trainee Grant
2010: OB-GYN best resident of the year- St. Joseph’s Hospital
RESEARCH INTERESTS
Current research interests include economic evaluations of gynecologic oncology interventions, health services and policy research in oncology and clinical and cost effectiveness of minimally invasive procedures. Her administrative role on the E4/F4 Quality Council is aligned with her interest in patient safety and quality in gynecologic oncology. She is an active teacher for the residents in obstetrics and gynecology and students in the MD program.
PUBLICATIONS
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Elit, L. and Kong, I., 2016. Outcomes of Stage IA Serous Endometrial Adenocarcinoma. Brachytherapy, 15, pp.S111-S112.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Pond, G., Memon, S., Elit, L. and Kong, I., 2016. 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. Radiotherapy and Oncology, 120, p.S83.
Donovan, E., Eiriksson, L., Reade, C., Kaur, H., Memon, S., Pond, G., Elit, L. and Kong, I., 2016. The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. International Journal of Radiation Oncology• Biology• Physics, 96(2), p.E315.
Jimenez, W., Maxwell, J., Daya, D., Sur, M., Elit, L., Eiriksson, L., Reade, C. and Lytwyn, A., 2015. UNDIFFERENTIATED ENDOMETRIAL CANCER, A DIFFERENT ENTITY WITH AN AGGRESSIVE BEHAVIOR: IGCS-0060 Uterine Cancer, including Sarcoma. International Journal of Gynecological Cancer, 25, p.69.
Lennox, G.K., Eiriksson, L.R., Reade, C.J., Leung, F., Mojtahedi, G., Atenafu, E.G., Ferguson, S.E., Murphy, J., Diamandis, E.P., Kulasingam, V. and Bernardini, M.Q., 2015. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. International Journal of Gynecological Cancer, 25(5), pp.809-814.
Tsoi, B., Blackhouse, G., Ferrazzi, S., Reade, C.J., Chen, I. and Goeree, R., 2015. Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and outcomes research, 7, p.213.
Elit, L. and Reade, C.J., 2015. Recommendations for follow-up care for gynecologic cancer survivors. Obstetrics & Gynecology, 126(6), pp.1207-1214.
Elit, L. and Reade, C.J., 2015. Recomendaciones para la Atención de Seguimiento a Sobrevivientes de Cáncer Ginecológico. Obstet Gynecol, 126, pp.1207-1214.
Covens, A., Vella, E.T., Kennedy, E.B., Reade, C.J., Jimenez, W. and Le, T., 2015. Sentinel lymph node biopsy in vulvar cancer: systematic review, meta-analysis and guideline recommendations. Gynecologic oncology, 137(2), pp.351-361.
Reade, C.J., McVey, R.M., Tone, A.A., Finlayson, S.J., McAlpine, J.N., Fung-Kee-Fung, M. and Ferguson, S.E., 2014. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. Journal of Obstetrics and Gynaecology Canada, 36(2), pp.133-140.
Bouchard-Fortier, G., Reade, C.J. and Covens, A., 2014. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecologic Oncology, 132(3):624-7.
Reade, C.J., Eiriksson, L.R. and Mackay, H., 2014. Systemic therapy in squamous cell carcinoma of the vulva: current status and future directions. Gynecologic oncology, 132(3), pp.780-789.
Reade, C.J.M., Habiba, U., Eiriksson, L.R., Cesari, M. and Osborne, R.J., 2014. Treatment of low-risk GTN with biweekly actinomycin-D. Gynecologic Oncology, 133, pp.185-186.
Eiriksson, L.R., Millar, H.C., Lennox, G.K., Reade, C.J.M., Leung, F., Diamandis, E.P., Kulasingam, V., Murphy, K.J., Ferguson, S.E. and Bernardini, M.Q., 2014. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology, 133, pp.82-83.
Eiriksson, L., Reade, C.J. and Elit, L., 2013. Meeting highlights: International Gynecologic Cancer Society (IGCS 2012). Gynecologic oncology, 128(1), pp.12-14.
Eiriksson, L.R., Reade, C.J., Lennox, G., Mojtahedi, G., Murphy, J., Ferguson, S.E. and Bernardini, M.Q., 2013. Ovarian cancer distribution of histology, stage, and screening performance. Journal of Clinical Oncology, 31, p.5543.
Reade, C., Tsoi, B., Tanvejsilp, P., Hanson, M., Marcotte, M. and Goeree, R., 2013. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. Gynecologic Oncology, 130(1), p.e41.
Reade, C.J., Finlayson, S., McAlpine, J., Tone, A.A., Fung-Kee-Fung, M. and Ferguson, S.E., 2013. Risk- reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. Journal of Obstetrics and Gynaecology Canada, 35(7), pp.627-634.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
Reade, C.J., Eiriksson, L.R. and Covens, A., 2013. Surgery for early stage cervical cancer: how radical should it be?. Gynecologic oncology, 131(1), pp.222-230.
Reade, C., Osborne, R., Shah, N., Eiriksson, L., Dodge, J., Moens, F. and Goeree, R., 2013. Treatment of low-risk gestational trophoblastic neoplasia: A probabilistic decision analysis model. Gynecologic Oncology, 130(1), pp.e27-e28.
Reade, C.J., Riva, J.J., Busse, J.W., Goldsmith, C.H. and Elit, L., 2013. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology, 130(3), pp.674-681.
J Reade, C., R Eiriksson, L. and Covens, A., 2012. A review of surgical options to preserve fertility in the treatment of early cervical cancer. Current Women’s Health Reviews, 8(3), pp.219-230.
Reade, C.J., Jimenez, W., O’Reilly, D. and Covens, A., 2012. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the Canadian health care context. Journal of Obstetrics and Gynaecology Canada, 34(11), pp.1053-1065.
Reade, C. and Elit, L., 2012. Trends in gynecologic cancer care in North America. Obstetrics and gynecology clinics of North America, 39(2), pp.107-129.
Reade, C., Hauspy, J., Schmuck, M.L. and Moens, F., 2011. Characterizing the learning curve for laparoscopic radical hysterectomy: buddy operating as a technique for accelerating skill acquisition. International Journal of Gynecological Cancer, 21(5), pp.930-935.
Julie Nguyen
MD
Assistant Professor
Gynecologic Oncology
Julie Nguyen is an Assistant Professor in the Department of Obstetrics and Gynecology at McMaster University. She is an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre (JHCC). She completed her residency and fellowship training at the University of Toronto. Upon completing a Masters of Science in Healthcare Improvement and Patient Safety, she has developed and published on several multidisciplinary perioperative improvement projects, including initiatives to decrease surgical site infections and thromboembolic events after Gynecologic Oncology surgery as well as an opioid stewardship strategy.
The main focus of her clinical research is to define the impact of frailty and aging on perioperative outcomes and tolerance to chemotherapy in Gynecologic Oncology to in turn develop strategies to optimize modifiable risk factors. She is the co-PI of the FARGO study, a multicenter prospective study which investigates the impact of frailty and its biomarkers on surgical and oncologic outcomes in patients over the age of 55. In parallel, she conducts population-level cohort studies utilizing databases such as CLSA, IC/ES, and NSQIP to further investigate frailty and aging. Her second focus of research is on equity, diversity and inclusion in the medical learning and working environments. She mentors numerous undergraduate and postgraduate students in research. She has been awarded greater than $800,000 in grant funding since 2020, from Hamilton Health Sciences (HHS), the Juravinski Hospital and Cancer Centre Foundation, the McMaster Institute for Research on Aging, HAHSO, the Population Health Research Institute and the Department of Obstetrics and Gynecology. She has received multiple awards including the Early Career Research Award from HHS, and the Most Promising Research award from the Department of Obstetrics and Gynecology.
Dr. Nguyen holds several leadership roles at both local and national levels. She serves as co-chair of the Gynecologic Oncology Disease Site Team at JHCC, as chair of the Business Unit, and co-chair of the Quality Improvement and Patient Safety Community of Practice, at the Society of Gynecologic Oncology of Canada. Additionally, she oversees the academic half-day curriculum for the Gynecologic Oncology Fellowship program at McMaster University.
For a comprehensive list of her publications, please visit her Google Scholar Profile: https://scholar.google.com/citations?user=W0CJcx8AAAAJ&hl=en&oi=sra
Julie Nguyen
MD
Assistant Professor
Gynecologic Oncology
Julie Nguyen is an Assistant Professor in the Department of Obstetrics and Gynecology at McMaster University. She is an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre (JHCC). She completed her residency and fellowship training at the University of Toronto. Upon completing a Masters of Science in Healthcare Improvement and Patient Safety, she has developed and published on several multidisciplinary perioperative improvement projects, including initiatives to decrease surgical site infections and thromboembolic events after Gynecologic Oncology surgery as well as an opioid stewardship strategy.
The main focus of her clinical research is to define the impact of frailty and aging on perioperative outcomes and tolerance to chemotherapy in Gynecologic Oncology to in turn develop strategies to optimize modifiable risk factors. She is the co-PI of the FARGO study, a multicenter prospective study which investigates the impact of frailty and its biomarkers on surgical and oncologic outcomes in patients over the age of 55. In parallel, she conducts population-level cohort studies utilizing databases such as CLSA, IC/ES, and NSQIP to further investigate frailty and aging. Her second focus of research is on equity, diversity and inclusion in the medical learning and working environments. She mentors numerous undergraduate and postgraduate students in research. She has been awarded greater than $800,000 in grant funding since 2020, from Hamilton Health Sciences (HHS), the Juravinski Hospital and Cancer Centre Foundation, the McMaster Institute for Research on Aging, HAHSO, the Population Health Research Institute and the Department of Obstetrics and Gynecology. She has received multiple awards including the Early Career Research Award from HHS, and the Most Promising Research award from the Department of Obstetrics and Gynecology.
Dr. Nguyen holds several leadership roles at both local and national levels. She serves as co-chair of the Gynecologic Oncology Disease Site Team at JHCC, as chair of the Business Unit, and co-chair of the Quality Improvement and Patient Safety Community of Practice, at the Society of Gynecologic Oncology of Canada. Additionally, she oversees the academic half-day curriculum for the Gynecologic Oncology Fellowship program at McMaster University.
For a comprehensive list of her publications, please visit her Google Scholar Profile: https://scholar.google.com/citations?user=W0CJcx8AAAAJ&hl=en&oi=sra
Nidhi Kumar Tyagi
MBChB, MSc, FRCPC
Medical Oncology
Nidhi Kumar Tyagi
MBChB, MSc, FRCPC
Medical Oncology
Elysia Donovan
MD, MSc, FRCPC, DABR
Radiation Oncology
Elysia Donovan
MD, MSc, FRCPC, DABR
Radiation Oncology
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.
Andra Nica
MD
Assistant Professor
Gynecologic Oncology
BIO
Dr. Andra Nica is an assistant professor in the Department of Obstetrics & Gynecology at McMaster University and an attending physician in the Division of Gynecologic Oncology at the Juravinski Hospital and Cancer Centre. She obtained her medical degree at Western University in 2013 and then completed her obstetrics and gynecology residency training at the University of Toronto in 2018. Subsequently, she pursued a fellowship in gynecologic oncology at The University of Toronto and a master’s in clinical epidemiology at the Institute of Health Policy, Management and Evaluation.
Her research interests include conducting population-based health services research, evaluation of patterns of cancer care, cancer screening and outcomes in patients with gynecologic malignancies, as well as determining long-term consequences of cancer care and improving the quality and safety of surgery.